Phillips-Medisize Wins Contract to Manufacture First Electronic-Enabled Combination Drug Delivery Product
22.10.2019 18:30:00 EEST | Business Wire | Press release
Phillips-Medisize, a Molex company, announced today an agreement with a leading biotechnology company to manufacture a wearable, electronic-enabled combination product. The product is a post-phase III development-stage combination drug and device that combines two-day, single use, disposable technology for subcutaneous drug delivery.
The wearable combination product – which is replaced every two days – is about the size of a hockey puck, and can either be adhered to the patient’s body, via an adhesive patch, or worn near the infusion site.
Phillips-Medisize, which built devices and supplied key data to support the FDA NDA submission, will provide final assembly, testing and quality control of this electronic combination product. Specifically, Phillips-Medisize will handle the prefilled drug cartridge that fits inside the device. This drug container is aseptically filled and shipped to Phillips-Medisize. Several state-of-the-art Phillips-Medisize facilities are involved in various stages of manufacturing the combination product – including molding, assembly, drug handling, labeling, reconciliation and more.
“This exciting new contract taps over 13 years of Phillips-Medisize’s combination product expertise, which includes cold chain drug handling and first programs with API handling. We have experience in manufacturing both combination and electronic-enabled drug delivery devices, and this is our first product submitted for FDA approval that includes both,” said Matt Jennings, CEO and President, Phillips-Medisize.
Pending receipt of FDA approval, Phillips-Medisize is contracted to provide commercialization services from its Hudson, WI-based manufacturing site. The combination product is slated for launch in 2H 2020. Backed by Phillips-Medisize’s scalability to move to high volume production, the product will be well positioned for a successful market launch.
Strong potential also exists to bring the device onto a connected health platform in the future, by embedding low-cost connectivity that will make it possible to capture and communicate data between patient and provider in order to help monitor adherence.
About Phillips-Medisize
Phillips-Medisize, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, medical device and specialty commercial market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions. For more information, please visit www.phillipsmedisize.com or www.molex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005826/en/
Contact information
For more information, contact:
Heather Ditzler
Phone +1 715-377-7261
heather.ditzler@phillipsmedisize.com
Paula Kasper (Europe)
Phone +41448383933
paula.kasper@phillipsmedisize.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. Bank Investment Services enhances investor and client onboarding experience for alternative investments3.8.2026 15:16:00 EEST | Press release
U.S. Bank Investment Services today announced it has gone live with a new client lifecycle management (CLM) platform, providing a comprehensive onboarding solution for alternative investment clients and the investors in their funds. The implementation is a key milestone in Investment Services’ multi-phased technology transformation strategy, aimed at modernizing processes, workflows and reporting across the private funds space. U.S. Bank leverages CLM provider Fenergo and its Fen-X platform. Fen-X automates many of the manual processes traditionally associated with underlying investors and direct client relationships and accelerates account setup while maintaining regulatory requirements. The enhanced onboarding experience provides investors and clients with more transparency throughout the process and enables integration with other solutions providers involved in the investor journey, such as screening and tax reporting. The investor experience has been further enhanced with an invest
Thales Launches Imperva for AWS to Help Organizations Protect Applications and APIs3.8.2026 15:00:00 EEST | Press release
Thales today announced the availability of Imperva for AWS, bringing its industry-leading web application firewall (WAF) to Amazon Web Services, Inc. (AWS) Marketplace as a SaaS offering. Built on key AWS services, Imperva for AWS helps organizations protect web applications and APIs against common cyber threats and malicious bot activity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803503864/en/ ©Thales The 2026 Thales Bad Bot Report found that automated traffic now accounts for 53% of all internet requests, with 27% of bot attacks targeting APIs directly. As attackers increasingly bypass user interfaces to operate at machine speed, organizations need application security that can keep pace without adding complexity. Imperva WAF delivers enterprise-grade protection natively on Amazon CloudFront. Unlike legacy content delivery network WAFs that route traffic outside the cloud provider network, Imperva WAF deploys direc
MEX Exchange, Part of MultiBank Group Strengthens Leadership Team with Key Appointment3.8.2026 14:39:00 EEST | Press release
MEX Exchange, the institutional electronic trading platform of MultiBank Group, today announced the appointment of Vibhanshu Bahuguna as Senior Director, reinforcing the company's commitment to building a world-class leadership team as it expands its global institutional business and technology capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803009139/en/ MEX Exchange, the institutional electronic trading platform of MultiBank Group, today announced the appointment of Vibhanshu Bahuguna as Senior Director, reinforcing the company's commitment to building a world-class leadership team as it expands its global institutional business and technology capabilities. With more than 20 years of experience across sales, business development and electronic trading, Bahuguna joins MEX Exchange with extensive expertise in electronic trading solutions spanning EMS, OMS, OTC and ECN technologies across the foreign exchange
NIQ Returns to IFA 2026 to Lead Industry Conversations on Growth, Innovation, AI and Consumer Transformation3.8.2026 13:45:00 EEST | Press release
As the Official Global Insights Partner of IFA Berlin 2026, NIQ (NYSE: NIQ) will continue to play a leading role shaping industry discussions , bringing together data, AI-driven intelligence, and human insight to illuminate the forces reshaping growth, innovation, and consumer behavior. Through executive keynotes, panel discussions, exclusive market intelligence, and strategic customer engagements (including participation in the IFA Retail Leaders Summit, the fourth NIQ Business Breakfast, and a dedicated SMB-focused event) NIQ will help translate rapid market change into actionable opportunity for the global technology ecosystem. Under this year’s IFA theme, “The Future Is Now,” NIQ will provide timely perspectives on the forces redefining consumer technology, home appliances, and retail—from AI-driven innovation and evolving shopper expectations to omnichannel transformation and emerging growth opportunities. As brands and retailers navigate economic uncertainty, shifting purchase be
Prodalim Reports Q2 2026 Results, with Continued Accelerated Growth in its Specialty Ingredients & Solutions Business3.8.2026 13:03:00 EEST | Press release
Tsahi Barak, Chairman of the Board and CEO of the Company, commented: "We are pleased to report another quarter of growth, highlighted by the increasing contribution of our Specialized Ingredients Solutions (SIS) business. We are clearly seeing the results of the transformation we have been leading over the past year, with revenue from our Specialized Ingredients Solutions business more than doubling compared to the same period last year. The business now contributes approximately 40% of the Group's adjusted EBITDA. We expect this trend to continue gaining momentum, while maintaining the stability and strong performance of our Juice Solutions business. We continue to reinvest the benefits of our growth in strengthening our operational infrastructure, recruiting key talent, and advancing innovative products that are entering commercialization . We believe these investments create a strong foundation for significant operating leverage that has yet to be fully realized, and we expect this
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom